SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe3/23/2016 9:07:50 PM
1 Recommendation

Recommended By
mulanoon2007

  Read Replies (1) of 4474
 
AP32788 Phase 1/2 trial listed on clinicaltrials.gov...

105 patients, 4 cohorts as follows, no specific diagnostic test for Exon 20.
Primary completion: February 2018.

1. EGFR Exon 20, TKI naive
2. Her2 Exon 20, TKI naive
3. EGFR or Her2 Exon 20 with CNS mets, TKI naive
4. EGFR or Her2 mutations incl. Exon 19, 21, T790M, G719X, S768I, L861Q, or L861R, TKI naive except 2L for Exon 19 & 21.

clinicaltrials.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News